121
Participants
Start Date
September 28, 2022
Primary Completion Date
May 18, 2024
Study Completion Date
May 18, 2024
D-0120
Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.
Benzbromarone
Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
Inner Mongolia Baogang Hospital, Baotou
Beijing Chao-yang Hospital, Capital Medical University, Beijing
Peking Union Medical College Hospital, Beijing
The First Hospital of Jilin University, Changchun
The First People's Hospital of Changzhou, Changzhou
Foshan Nanhai People's Hospital, Foshan
Guangzhou First People's Hospital, Guangzhou
Nanfang Hospital, Guangzhou
The Second People's Hospital of Guangdong Province, Guangzhou
Zhujiang Hospital of Southern Medical University, Guangzhou
The First Affiliated Hospital Of University Of South China, Hengyang
Huzhou Third People's Hospital, Huzhou
First Affiliated Hospital of Kunming Medical University, Kunming
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
Affiliated Hospital of North Sichuan Medical College, Nanchong
Gulou Hospital Affiliated to Nanjing University Gulou Hospital Affiliated to Nanjing University, Nanjing
Zhongda Hospital Southeast University, Nanjing
Affiliated Hospital of Nantong University, Nantong
Ningbo Huamei Hospital, University of Chinese Academy of Sciences, Ningbo
Changhai Hospital of Shanghai, Shanghai
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Qinghai Province People's Hospital, Xining
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Zigong Fourth People's Hospital, Zigong
Lead Sponsor
InventisBio Co., Ltd
INDUSTRY